Zentalis Pharmaceuticals, Inc. (ZNTL)

NGM – Real Time Price. Currency in USD

4.26

+0.15 (3.56%)

Market open: Aug 12, 2026, 3:26 PM EDT

4.11

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

06.08.2026

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

Following U.S. regulatory discussions, accelerated approval strategy remains intact, supported by DENALI Part 2 Enrollment completed in Part 2a and 2b of the DENALI trial; Part 2c is enrolling DENALI Part 2 topline readout expected in 1H 2027 to allow for data maturation post full enrollment $174.6 million in cash, cash equivalents and marketable securities as of June 30, 2026, providing runway into late 2027 to support execution of key milestones SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced financial results for the second quarter ended June 30, 2026, and highlighted recent corporate, regulatory and clinical progress and upcoming expected milestones. "We have achieved important milestones on the continued advancement of azenosertib in our registration-intended DENALI Phase 2 and ASPENOVA Phase 3 trials for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC), including completing the enrollment of DENALI Part 2b and aligning with the U.S. Food and Drug Administration (FDA) following a Type D meeting on our selected dose and DENALI study population to support potential accelerated approval,” said Julie Eastland, Chief Executive Officer of Zentalis.

03.08.2026

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on August 3, 2026, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 84,000 shares of the Company's common stock to two (2) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).

Videos

No Data

There is no data to display

Press releases

06.08.2026

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

03.08.2026

Zentalis Pharmaceuticals, Inc. (ZNTL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Zentalis Pharmaceuticals, Inc. (ZNTL)

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Videos

No Data

Press releases

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Videos

No Data

Press releases

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Zentalis Pharmaceuticals, Inc. (ZNTL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Zentalis Pharmaceuticals, Inc. (ZNTL)

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Videos

No Data

Press releases

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Videos

No Data

Press releases

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)